pharma · HIV-1 Infection · HIV-1 infection
Gilead Sciences
Gilead Sciences Pty Limited
Gilead Sciences Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include HIV-1 Infection, HIV-1 infection, Primary Biliary Cholangitis, Non-small cell lung cancer, Locally Advanced/Metast
333 Lakeside Drive, Foster City, CA 94404, US HQ
1987 Founded
14,602 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 30
- Drugs
- 54
- Patents
- 0
GS-US-600-6165
Phase 3 · small molecule · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
GS-US-600-6165 for Extensive Stage Small Cell Lung Cancer (ES-SCLC) is a Phase 3 program (small_molecule) at Gilead Sciences Pty Limited with 1 ClinicalTrials.gov record(s).
Internal code GS-US-600-6165
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Gilead Sciences Pty Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Status
- active
- Trials
- 1